Hematologic Diseases Clinical Trial
Official title:
A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent β-Thalassemia
Verified date | November 2023 |
Source | Vertex Pharmaceuticals Incorporated |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in subjects with transfusion-dependent β-thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.
Status | Active, not recruiting |
Enrollment | 45 |
Est. completion date | August 2024 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 35 Years |
Eligibility | Key Inclusion Criteria: - Diagnosis of transfusion-dependent ß-thalassemia (TDT) as defined by: 1. Documented homozygous ß-thalassemia or compound heterozygous ß-thalassemia including ß-thalassemia/hemoglobin E (HbE). Subjects can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning. 2. History of at least 100 mL/kg/year or =10 units/year of packed RBC transfusions in the prior 2 years before signing the consent or the last rescreening for patients going through re-screening. - Eligible for autologous stem cell transplant as per investigator's judgment. Key Exclusion Criteria: - A willing and healthy 10/10 Human Leukocyte Antigen (HLA)-matched related donor is available per investigator's judgement. - Prior allo-HSCT. - Subjects with associated a-thalassemia and >1 alpha deletion or alpha multiplications. - Subjects with sickle cell beta thalassemia variant. - Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator. - White blood cell (WBC) count <3 × 10^9/L or platelet count <50 × 10^9/L not related to hypersplenism. Other protocol defined Inclusion/Exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Canada | The Hospital for Sick Children | Toronto | |
Canada | British Columbia Children's Hospital | Vancouver | |
Germany | Universitätsklinikum Düsseldorf Hospital Duesseldorf | Düsseldorf | |
Germany | Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine | Regensburg | |
Germany | University Hospital Tübingen | Tuebingen | |
Italy | Ospedale Pediatrico Bambino Gesù, IRCCS | Rome | |
United Kingdom | Imperial College Healthcare NHS Trust, Hammersmith Hospital | London | |
United Kingdom | University College London Hospitals NHS Foundation Trust | London | |
United States | Ann & Robert Lurie Children's Hospital of Chicago | Chicago | Illinois |
United States | The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers | Nashville | Tennessee |
United States | Columbia University Medical Center | New York | New York |
United States | Columbia University Medical Center (21+ years) | New York | New York |
United States | Lucile Packard Children's Hospital | Palo Alto | California |
United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Vertex Pharmaceuticals Incorporated | CRISPR Therapeutics |
United States, Canada, Germany, Italy, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of subjects achieving transfusion independence for at least 12 consecutive months (TI12) | From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion] | ||
Primary | Proportion of subjects with engraftment (first day of 3 consecutive measurements of absolute neutrophil count [ANC] =500/µL on three different days) | Within 42 days after CTX001 infusion | ||
Primary | Time to neutrophil and platelet engraftment | Days post-infusion to engraftment | ||
Primary | Frequency and severity of collected adverse events (AEs) | Signing of informed consent through Month 24 visit | ||
Primary | Incidence of transplant-related mortality (TRM) | Baseline (pre-transfusion) to 100 days and 1 year post-CTX001 infusion | ||
Primary | All-cause mortality | Signing of informed consent through Month 24 visit | ||
Secondary | Proportion of subjects achieving transfusion independence for at least 6 consecutive months (TI6) | From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion | ||
Secondary | Proportion of subjects achieving at least 95 percent (%), 90%, 85%, 75%, and 50% reduction from baseline in annualized transfusions 60 days after CTX001 infusion | From Day 60 up to 24 months post-CTX001 infusion | ||
Secondary | Relative change from baseline in transfusions 60 days after CTX001 infusion | From Day 60 up to 24 months post-CTX001 infusion | ||
Secondary | Duration of transfusion free in subjects who have achieved TI12 | From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion | ||
Secondary | Proportion of alleles with intended genetic modification in peripheral blood leukocytes over time | Day 1 CTX001 infusion through Month 24 visit | ||
Secondary | Proportion of alleles with intended genetic modification present in CD34+ cells of bone marrow over time | Day 1 CTX001 infusion through Month 24 visit | ||
Secondary | Change in fetal hemoglobin concentration over time | Baseline (pre-transfusion) through Month 24 visit | ||
Secondary | Change in total hemoglobin concentration over time | Baseline (pre-transfusion) through Month 24 visit | ||
Secondary | Change in health-related quality of life (HRQoL) from baseline over time using EuroQol Questionnaire (5 dimensions - 5 levels of severity - EQ-5D-5L) | The EQ-5D-5L Questionnaire consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The EQ-5D comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and 5 levels: no problems to extreme problems. The subject marks the most appropriate statement in each dimension, resulting in a 1-digit number for that dimension. The digits can be combined in a 5-digit number describing the subject's health state. The EQ VAS records the subject's self-rated health on a 100-point VAS, endpoints labelled "the best health you can imagine" and "the worst health you can imagine." | Screening visit through Month 24 visit | |
Secondary | Change in health-related quality of life (HRQoL) from baseline over time using the Functional assessment of cancer therapy-bone marrow transplant questionnaire (FACT-BMT) | The FACT-BMT Questionnaire includes physical, social, family, emotional, and functional well-being, and treatment specific concerns of bone marrow transplantation. Each statement has a 5-point Likert-type response scale ranging from 0=not at all to 4=very much. The subject marks one number per line as it applies to the past 7 days. Questionnaires are scored; the higher the score, the better the QOL. | Screening visit through Month 24 visit | |
Secondary | Change in patient reported outcome (PRO) over time assessed using EQ-5D-Youth (EQ-5D-Y) | Screening visit through Month 24 visit | ||
Secondary | Change in PRO over time assessed using pediatric quality of life inventory (PedsQL) | Screening visit through Month 24 visit | ||
Secondary | Changes in liver iron concentration (LIC) and cardiac iron content (CIC) and ferritin parameters of iron overload | Screening visit through Month 24 visit | ||
Secondary | Proportion of subjects receiving iron chelation therapy | 1 month post-CTX001 infusion through Month 24 visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04094844 -
Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation
|
N/A | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Recruiting |
NCT03918343 -
Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
|
N/A | |
Completed |
NCT01445561 -
Ultra Low Dose Interleukin-2 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT06148610 -
Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
|
||
Completed |
NCT04168983 -
Impact of Sophrology on the Pain Felt During a Bone Marrow Aspiration and Biopsy
|
N/A | |
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Completed |
NCT01108159 -
Integrated Whole-Genome Analysis of Hematologic Disorders
|
||
Completed |
NCT00800839 -
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
|
Phase 2 | |
Completed |
NCT00213239 -
A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children
|
Phase 1/Phase 2 | |
Terminated |
NCT00208949 -
A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF
|
Phase 2 | |
Terminated |
NCT00176826 -
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
|
Phase 2/Phase 3 | |
Completed |
NCT00208962 -
Allogeneic Cell Therapy for Adults With Hematologic Malignancies
|
Phase 2 | |
Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
Completed |
NCT00000587 -
Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection
|
Phase 2 | |
Recruiting |
NCT05487794 -
Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men With Erythrocytosis
|
N/A | |
Completed |
NCT03611257 -
Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases
|
N/A | |
Completed |
NCT02827149 -
High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT
|
||
Completed |
NCT04584528 -
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
|
N/A |